Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="1"><hr/></td></tr><tr class="thead"><td align="left">Indications and applications for dedicated breast PET</td></tr><tr><td class="thead-hr" colspan="1"><hr/></td></tr><tr><td align="left">Screening in dense breasts, hindering mammography/ultrasound</td></tr><tr><td align="left">Screening in (very) high-risk patients</td></tr><tr><td align="left">Occult lesion on conventional imaging</td></tr><tr><td align="left">Inconclusive lesion on mammography/ultrasound</td></tr><tr><td align="left">Accurate FDG uptake determination in heterogeneous lesions</td></tr><tr><td align="left">Primary tumor response monitoring (in node-negative patients)</td></tr><tr><td align="left">FDG-guided biopsies</td></tr><tr class="table-tr"><td colspan="1"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>Abbreviations: PET: positron emission tomography, FDG: fluorodeoxyglucose.<br/></td></tr></table>

Possible indications and applications for dedicated breast PETs in future clinical practice.

Journal of Oncology

tab2

Table 2

Table 2: Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET 